Ravidasvir hydrochloride is primarily used in the treatment of chronic hepatitis C virus (HCV) infections. It functions as an NS5A inhibitor, targeting a specific protein essential for viral replication. This makes it effective in reducing viral load and preventing the progression of liver disease. It is often used in combination with other antiviral agents, such as sofosbuvir, to enhance efficacy and achieve higher cure rates. The drug is particularly beneficial for patients with different HCV genotypes, offering a broad-spectrum therapeutic option. Its application is crucial in regions with high HCV prevalence, contributing to improved public health outcomes by reducing transmission and complications associated with the infection.